Adaptive Biotechnologies Balance Sheet Health
Financial Health criteria checks 5/6
Adaptive Biotechnologies has a total shareholder equity of $274.8M and total debt of $131.5M, which brings its debt-to-equity ratio to 47.9%. Its total assets and total liabilities are $620.3M and $345.6M respectively.
Key information
47.9%
Debt to equity ratio
US$131.55m
Debt
| Interest coverage ratio | n/a |
| Cash | US$308.87m |
| Equity | US$274.77m |
| Total liabilities | US$345.56m |
| Total assets | US$620.32m |
Recent financial health updates
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Recent updates
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Our First Assessment On Adaptive Biotechnologies
Dec 16Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Sep 26Financial Position Analysis
Short Term Liabilities: ADPT's short term assets ($374.0M) exceed its short term liabilities ($83.0M).
Long Term Liabilities: ADPT's short term assets ($374.0M) exceed its long term liabilities ($262.6M).
Debt to Equity History and Analysis
Debt Level: ADPT has more cash than its total debt.
Reducing Debt: ADPT's debt to equity ratio has increased from 0% to 47.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADPT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ADPT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.5% each year